Citius Pharmaceuticals (CTXR) Competitors $0.92 -0.09 (-8.91%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. QNCX, KRON, VTVT, ARTV, RNXT, PEPG, AVTX, MRSN, BLUE, and CUEShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Quince Therapeutics (QNCX), Kronos Bio (KRON), vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), RenovoRx (RNXT), PepGen (PEPG), Avalo Therapeutics (AVTX), Mersana Therapeutics (MRSN), bluebird bio (BLUE), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors Quince Therapeutics Kronos Bio vTv Therapeutics Artiva Biotherapeutics RenovoRx PepGen Avalo Therapeutics Mersana Therapeutics bluebird bio Cue Biopharma Quince Therapeutics (NASDAQ:QNCX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Do analysts prefer QNCX or CTXR? Quince Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 566.67%. Citius Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 5,823.91%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has stronger valuation & earnings, QNCX or CTXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.39-0.86Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Is QNCX or CTXR more profitable? Citius Pharmaceuticals' return on equity of -51.69% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Citius Pharmaceuticals N/A -51.69%-37.60% Which has more risk and volatility, QNCX or CTXR? Quince Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Does the media favor QNCX or CTXR? In the previous week, Citius Pharmaceuticals had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 8 mentions for Citius Pharmaceuticals and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Citius Pharmaceuticals' score of 0.49 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in QNCX or CTXR? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer QNCX or CTXR? Citius Pharmaceuticals received 204 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Quince Therapeutics an outperform vote while only 62.21% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes1090.91% Underperform Votes19.09%Citius PharmaceuticalsOutperform Votes21462.21% Underperform Votes13037.79% SummaryQuince Therapeutics beats Citius Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.04M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.116.597.064.69Net Income-$39.14M$143.75M$3.23B$248.14M7 Day Performance7.50%3.72%2.67%2.39%1 Month Performance17.86%11.01%8.82%6.05%1 Year Performance-94.30%3.87%31.44%13.60% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.4306 of 5 stars$0.92-8.9%$54.50+5,823.9%-93.7%$9.04MN/A0.0020News CoverageAnalyst ForecastGap DownQNCXQuince Therapeutics3.6977 of 5 stars$1.17flat$8.00+583.8%+58.6%$53.20MN/A-0.9460Positive NewsKRONKronos Bio3.3095 of 5 stars$0.87-0.2%$1.63+86.8%-24.2%$53.04M$9.19M-0.61100Short Interest ↑VTVTvTv Therapeutics1.7082 of 5 stars$16.10-1.3%$35.50+120.5%-9.2%$51.44M$17K-3.559ARTVArtiva Biotherapeutics2.6257 of 5 stars$2.11+0.5%$19.40+819.4%N/A$51.41M$251K0.0081News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionRNXTRenovoRx2.9636 of 5 stars$1.37-1.4%$7.25+429.2%+29.5%$50.10M$240K-2.406Positive NewsShort Interest ↓PEPGPepGen2.7556 of 5 stars$1.52+1.3%$7.67+404.4%-91.9%$49.74MN/A-0.5130Trending NewsGap DownAVTXAvalo Therapeutics3.6048 of 5 stars$4.56+11.2%$30.00+557.9%-57.3%$49.38M$441K0.0040News CoverageShort Interest ↓Gap UpHigh Trading VolumeMRSNMersana Therapeutics4.1176 of 5 stars$0.39+1.3%$5.20+1,230.6%-83.2%$48.71M$34.01M-0.64150BLUEbluebird bio3.4038 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520Positive NewsCUECue Biopharma4.4783 of 5 stars$0.64-0.6%$3.00+371.0%-56.5%$48.00M$7.99M-0.7160Gap Down Related Companies and Tools Related Companies QNCX Competitors KRON Competitors VTVT Competitors ARTV Competitors RNXT Competitors PEPG Competitors AVTX Competitors MRSN Competitors BLUE Competitors CUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTXR Stock Free CTXR Stock Alerts